Advertisement

Topics

Emerging generic API hubs unlikely to challenge India and China, says analyst

07:56 EST 8 Nov 2017 | in-PharmaTechnologis

Emerging countries face significant barriers to becoming API manufacturing hubs, keeping India and China the dominant suppliers to regulated pharma markets, says a Clarivate Analytics analyst.

Original Article: Emerging generic API hubs unlikely to challenge India and China, says analyst

NEXT ARTICLE

More From BioPortfolio on "Emerging generic API hubs unlikely to challenge India and China, says analyst"

Advertisement
Quick Search
Advertisement
Advertisement